PMID: 6110956Apr 4, 1981Paper

Delayed alloimmunisation by random single donor platelet transfusions. A randomised study to compare single donor and multiple donor platelet transfusions in cancer patients with severe thrombocytopenia

Lancet
K SintnicolaasB Löwenberg

Abstract

The effects of single-donor (SD) and multiple-donor (MD) platelet transfusions in 34 cancer patients with severe thrombocytopenia and haemorrhages were compared in a randomised study. Platelet recovery values in both groups were similar after the first transfusion. After the second transfusion platelet recovery values were significantly better in those receiving SD transfusions. Platelet recovery values gradually declined with subsequent MD transfusions. These results suggest early alloimmunisation in the MD transfused patients only. MD transfusions were estimated to be no longer effective after about nine transfusions. Platelet recovery values were better indicators of early sensitisation than was the lymphocytotoxicity test. Restriction of the number of donors per transfusion may postpone the development of refractoriness to random-donor platelet transfusions in thrombocytopenic patients.

References

May 11, 1976·Cancer·C A SchifferJ M Joseph
May 3, 1962·The New England Journal of Medicine·L A GAYDOSN MANTEL

❮ Previous
Next ❯

Citations

Jun 9, 2004·Blood Reviews·Joanna Mary Heal, Neil Blumberg
Dec 20, 1999·Transfusion Medicine Reviews·L A Chambers, J H Herman
Mar 25, 1982·The New England Journal of Medicine·B M CamittaE D Thomas
Jul 22, 1982·The New England Journal of Medicine·C A Schiffer, S J Slichter
Jan 7, 1998·The New England Journal of Medicine·UNKNOWN Trial to Reduce Alloimmunization to Platelets Study Group
Feb 4, 1989·BMJ : British Medical Journal·A J RamirezR D Rubens
Jun 1, 1999·Leukemia & Lymphoma·I J Webb, K C Anderson
Nov 13, 2001·Reviews in Clinical and Experimental Hematology·P Rebulla
Feb 1, 1987·World Journal of Surgery·S Murphy
Jan 1, 1993·Acta neurochirurgica·Y NakasuJ Handa
Jan 1, 1992·Journal of Clinical Apheresis·M K EliasC T Smit Sibinga
Oct 3, 1999·Archives of Pathology & Laboratory Medicine·S Silberman
Jan 1, 1995·Transfusion clinique et biologique : journal de la Société française de transfusion sanguine·G Andreu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.